Peter Attia argues optimization differs from risk reduction. For TRT, the line depends on the patient. This primer maps the clinical evidence for both categories.
Peter Attia argues optimization differs from risk reduction. For TRT, the line depends on the patient. This primer maps the clinical evidence for both categories.
The honest answer: both, depending on the patient. For a man with confirmed hypogonadism, defined as total testosterone at or below 300 ng/dL paired with symptoms, testosterone replacement therapy is disease treatment with validated clinical outcomes. For a man whose levels are normal and whose symptoms are vague, it moves closer to optimization, and the evidence bar shifts accordingly.
Peter Attia draws a useful line between interventions that reduce a known, quantifiable risk and those that speculatively push a biomarker in a favorable direction. The distinction matters because the acceptable risk-to-benefit calculation differs between the two. A diabetic patient taking insulin and a healthy person experimenting with glucose-lowering supplements are doing very different things, even if they share a mechanism.
TRT straddles that line. The European Association of Urology's 2026 guidelines recommend a threshold of 12 nmol/L (roughly 346 ng/dL) for diagnosing symptomatic male hypogonadism, and they require that biochemical findings align with actual symptoms before treatment begins [1]. That pairing of lab value plus clinical picture is what separates disease treatment from elective optimization.
A 2026 cross-sectional study in Andrology found that men with erectile dysfunction and lower calculated free testosterone showed significantly worse erectile function scores and higher depression scores compared to those with higher free testosterone [2]. A borderline lab result in a genuinely symptomatic man is not a gray area; it is a clinical signal.
Where a patient lands on the treatment-vs.-optimization spectrum depends on two things: what the numbers say, and what the body is telling you. Getting that diagnosis right is where the clinical work begins.
When a man meets the clinical definition of hypogonadism, the evidence behind TRT shifts from speculative to trial-tested. The question is no longer "might this help?" but "what does the randomized data say?" The answer, for cardiovascular outcomes specifically, is more reassuring than the old warning labels suggested.
The TRAVERSE trial, a large randomized controlled study published in 2023, tested TRT directly against placebo in men with hypogonadism who already carried established cardiovascular disease or elevated cardiovascular risk. The result: testosterone was non-inferior to placebo for major adverse cardiovascular events, the combined measure of heart attack, stroke, and cardiovascular death [3]. A 2026 meta-analysis of 41 randomized controlled trials reached the same conclusion, reporting a pooled odds ratio of 0.83 for MACE, with a confidence interval that crossed 1.0, meaning no statistically significant increase in risk [4].
Put plainly: in men who genuinely need testosterone, the therapy does not appear to raise the risk of heart attack or stroke.
TRAVERSE did raise two signals worth monitoring: higher rates of atrial fibrillation (an irregular heart rhythm) and pulmonary embolism (a blood clot in the lungs) in the testosterone group [3]. These are not reasons to avoid TRT in appropriate candidates, but they are reasons to screen carefully and follow patients with a structured monitoring plan, a point this clinic builds into every protocol. You can read more about the full cardiovascular picture at TRT and long-term safety.
The risk of doing nothing is not zero. Low testosterone is independently associated with higher prevalence of metabolic syndrome, a cluster of conditions including excess abdominal fat, elevated blood sugar, and abnormal lipid levels that together drive cardiovascular and diabetes risk [5]. GLP-1 receptor agonists improve testosterone levels partly through metabolic improvements, supporting the idea that the testosterone-metabolism link runs in both directions [6].
| Risk Domain | Evidence Direction |
|---|---|
| MACE (heart attack, stroke) | TRT non-inferior to placebo in high-risk men [4] |
| Atrial fibrillation | Signal of increased risk in TRAVERSE [3] |
| Pulmonary embolism | Signal of increased risk, especially early
Attia's caution lands hardest here, and it is largely correct. When a man already has normal testosterone levels and chooses to push them higher, the benefit side of the ledger gets thin while the risk side stays constant. That is a different calculation than treating confirmed hypogonadism.
The cognitive research makes the point precisely. A 2007 randomized trial in Psychoneuroendocrinology found that healthy older men who achieved moderate increases in testosterone showed meaningful improvements in verbal and spatial memory. Men pushed to large, supraphysiologic increases did not [7]. A follow-up study using positron emission tomography, a brain-imaging technique that measures glucose metabolism in different regions, found that supraphysiologic doses, achieved by doubling testosterone with 200 mg injections every two weeks, actually decreased verbal memory performance [8]. Put plainly: there appears to be a range where testosterone supports brain function, and exceeding it does not help and may hurt.
This is what "supraphysiologic" means in practice: levels the body would never produce on its own, achieved only through exogenous dosing. For cognition at least, more is not better.
When benefit is clear, manageable risks are worth accepting. When benefit is speculative, the same risks deserve more weight. For eugonadal men considering TRT, the clinically relevant risks include:
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
If benefit is marginal,
If benefit is marginal, the right question is: marginal compared to what baseline? A clear lab picture answers that. Three numbers do most of the work: total testosterone, free testosterone, and SHBG. Together they tell you whether you are treating a deficit or dialing a preference.
Total testosterone is the opening number, but it is not the final one. SHBG (sex hormone-binding globulin, a protein that grabs testosterone and holds it in an inactive form) can be elevated enough to leave a man functionally deficient even when his total T reads normal. A cross-sectional study of nearly 6,000 Chinese men found that both total and free testosterone were independently and inversely associated with hypertension prevalence, confirming that the bioactive fraction matters for real outcomes, not just symptom scoring [10]. European urology guidelines now recommend calculating free T whenever SHBG is likely altered, because total T alone can misclassify the patient [1].
Diagnosis also requires two separate fasting morning draws, taken between 7 and 10 AM, before a physician can confirm hypogonadism [1]. One low reading on an afternoon, non-fasting sample is not a diagnosis. Put plainly: the timing and conditions of your blood draw change the number enough to shift your category.
LH (luteinizing hormone, the pituitary's signal telling your testes to produce testosterone) and FSH (its partner signal for sperm production) distinguish whether the problem originates in the testes or higher up in the brain's control system. That distinction shapes treatment, not just the testosterone number itself. In men with diabetes, BMI and elevated estradiol emerged as independent predictors of hypogonadism, illustrating that metabolic context reshapes the entire hormonal picture [5].
| Biomarker | Treatment-range finding | Optimization-range finding |
|---|
| Total testosterone | Below 300 ng/dL (or ≤12 nmol/L) on two morning fasting draws [1] | 300-500 ng/
The goal on the prescription pad changes almost everything: the delivery method, the dose target, the co-prescriptions, and how tightly you monitor. A man treating confirmed hypogonadism needs a protocol built around correcting a deficiency and protecting hard outcomes. A eugonadal man pursuing optimization needs a narrower intervention and a shorter leash.
Testosterone cypionate, injected subcutaneously or intramuscularly, is the workhorse for both groups because it is titratable and predictable. For a hypogonadal man, the dose targets symptom resolution and a total testosterone level that lands in a physiologically normal range, not the top of the reference chart. For an optimization candidate, smaller doses and tighter intervals matter more, because the margin between "a little more" and supraphysiological territory is narrower when baseline levels are already adequate [8][7].
hCG in a TRT protocol belongs in nearly every treatment protocol from day one. Human chorionic gonadotropin, or hCG, mimics the pituitary signal that keeps the testes active and maintains testicular volume and sperm production. Without it, exogenous testosterone shuts down that signal within weeks. For an optimization candidate with fertility plans, this co-prescription is non-negotiable [9].
Choosing the right delivery method is only half of the protocol. The other half is a monitoring schedule that catches problems before they compound. The American Family Physician review notes that serum testosterone, hematocrit, and PSA should be measured at baseline and at least annually in men over 40 on TRT, with most physicians running a 6-to-12-week check after any dose change [9].
| Safety marker | Why it matters | Action threshold |
|---|---|---|
| Hematocrit | TRT thickens blood by stimulating red-cell production | Dose reduction or phlebotomy typically considered above 54% |
| PSA |
Before any prescription is written, two things must be true: symptoms and lab confirmation, both together. The Endocrine Society and American Family Physician guidelines state that testosterone deficiency requires "persistently low serum testosterone levels in the setting of symptoms consistent with testosterone deficiency" before initiating therapy [9]. One without the other is not a diagnosis.
Bring these questions to your first consultation:
If all five boxes have clear answers, you and your clinician have what you need to make a genuinely informed decision.
It depends on your lab values and symptoms. For men with confirmed hypogonadism (testosterone at or below 300 ng/dL plus symptoms), testosterone replacement therapy is disease treatment with validated clinical outcomes. For men whose testosterone levels are already normal but who want higher levels, it shifts toward optimization, and the evidence bar for safety becomes higher because the potential benefit is less clear.
For men with confirmed hypogonadism, recent data are reassuring. The TRAVERSE trial found that testosterone was non-inferior to placebo for major heart attacks, strokes, and cardiovascular death. A 2026 meta-analysis of 41 randomized trials reached the same conclusion. However, the TRAVERSE trial did identify higher rates of irregular heart rhythm (atrial fibrillation) and blood clots in the lungs that warrant careful screening and monitoring in appropriate candidates.
You need total testosterone, free testosterone, and SHBG (sex hormone-binding globulin), measured on at least two separate fasting mornings between 7:00 and 10:00 AM. You should also measure LH and FSH to determine whether the problem is in your testes or your brain's control system. Diagnosis requires lab confirmation paired with actual symptoms, not just a low number on one test.
Research suggests there is an optimal range, but exceeding it does not help. A randomized trial found that healthy older men with moderate testosterone increases showed meaningful improvements in verbal and spatial memory, but men given large supraphysiologic doses actually showed decreased verbal memory. In other words, more testosterone does not equal better cognition.
Key risks include thickened blood from increased red blood cell production (requiring hematocrit monitoring), suppression of sperm production (important if you plan biological children), and worsening of sleep apnea. These risks deserve more weight when the benefit of therapy is marginal compared to a man with confirmed hypogonadism who clearly needs treatment. Baseline screening and regular monitoring are essential parts of any protocol.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.